

IMMUNO-TROL



For Tracker  assay validation

A range of ready to use, internal Quality Control sera, dedicated to the pharmacological dosages of biotherapies and CE marked.



IMMUNO-TROL Tracker

IMMUNO-TROL sera are Internal Quality Controls (IQC) for the routine validation of pharmacological dosages of biotherapies (drug and anti-drug antibodies).

EASY-TO-USE

- Liquid control, ready to use
- Standardized protocols
- Identical use and reactivity as patients samples

RELEVANT

- Universal multi-parametric controls
- Stable material suitable for intra and inter assay validation

ACCURATE

- Monitor potential drift of analytical systems
- Quality assurance for assay validation



For i-Tracker 

Reference	Designation	Packaging
CTx 002-PC	Immuno-Trol Drug: Positive control two levels	2 x 500 µl
CTx 003-PC	Immuno-Trol anti-Drug: Positive control two levels	2 x 1,5 ml

x = Infliximab / Adalimumab / Vedolizumab / Ustekinumab / Golimumab / Rituximab / Certolizumab Pegol (Etanercept, Tocilizumab, Risankizumab, Natalizumab et Ocrelizumab: in development)

For LISA TRACKER 

Reference	Designation	Packaging
LTx 002-PC	Immuno-Trol Drug: Positive control two levels	2 x 250 µl
LTx 003-PC	Immuno-Trol anti-Drug: Positive control two levels	2 x 1 ml

x = Infliximab / Adalimumab / Etanercept / Certolizumab Pegol / Golimumab / Rituximab / Secukinumab / Tocilizumab / Bevacizumab / TRastuzumab / Ustekinumab / Vedolizumab

For ez-Tracker 

Reference	Designation	Packaging
ETx 002-C / ETx 003-C	ez-Tracker Drug / ADAs Controls	2 x 1 mL
ETx 002-CAL / ETx 003-CAL	ez-Tracker Drug / ADAs Calibrators	2 x 1 mL

x = Infliximab / Adalimumab / Golimumab (Vedolizumab, Ustekinumab, Rituximab et Etanercept in development)



Theradiag (France) - Boditech (South Korea)



14 rue Ambroise Croizat
77183 Croissy Beaubourg
France

Phone : +33 (0) 1 64 62 10 12
Fax : +33 (0) 1 64 62 09 66
info@theradiag.com
www.theradiag.com



Read carefully the instruction for use of the product insert before use. Pictures may differ from actual products.

I-T Tracker-V.12/2022 - EN